MEMORANDUM AND ORDER
This is an antitrust action raising federal and state law claims. This ease is before the court upon the motions to dismiss for failure to state a claim (Doc. Nos. 23 and 27) filed by defendant Owens & Minor Distribution, Inc. and defendant Cardinal Health 200, LLC.
Plaintiff alleges federal and state antitrust law violations and makes a claim of unjust enrichment relating to the distribution and sale of “med-surg” supplies to acute care providers. “Med-surg” supplies are medical and surgical single-use items such as sutures, needles, syringes, gloves, surgical instruments and catheters. There are thirty product categories in the “medsurg basket” commonly sold to acute care providers. Plaintiff alleges that defendants Owens & Minor Distribution, Inc. (“0 & M”) and Cardinal Health 200, LLC (“Cardinal”) are broad-based distributors who purchase and distribute the full gamut of products in the med-surg basket. The complaint alleges that there are approximately 4,800 acute care providers that commonly purchase med-surg supplies through group purchasing organizations, regional purchasing cooperatives or other multi-hospital systems. Defendant O & M is alleged to have 39% of this market. Defendant Cardinal is alleged to have 33% of this market.
Plaintiff has limited its business to a portion of the med-surg basket — the sale and distribution of sutures and endomechanical products. Endomechanical (“endo”) products are devices used in minimally invasive surgeries, like laparoscopic surgery. Sutures and endo products are alleged to make up 10% of med-surg supplies distributed in the United States to acute care providers. Plaintiff asserts that it provides a greater variety of suture and endo products than the more broad-based distributors who concentrate on so-called “core” products, which are the most popular or widely-used sutures and endo products. Plaintiff alleges that it is the only significant distributor of specialty or non-core sutures and endo products. For this and other reasons, plaintiff contends that its business thrived from the beginning in 1998 through 2008. Plaintiff alleges that it distributes to approximately 900 of the nation’s 4,800 acute care providers and that it offers both core and non-core sutures and endo products.
Plaintiff states that in 2008 defendants attempted to leverage their power in the distribution of a fuller array of med-surg products to coerce customers from buying plaintiffs sutures and endo products. Plaintiff asserts that contracts were constructed which unlawfully tied the sale of sutures and endo products to the sale of other products in the med-surg basket. Under these contracts if an acute care provider did not purchase 90% or more of its sutures and endo products from a defendant, then it would pay a penalty on the entire med-surg basket purchased from that defendant. The penalty was allegedly so substantial that it effectively prevented acute care providers from dealing with plaintiff, thus foreclosing the opportunity for acute care providers to enjoy plaintiffs alleged superior service, lower distribution fees and comprehensive product selection. According to plaintiff, this penalty was also packaged as a “discount program” where providers were not eligible for a discounted distribution fee if they did not purchase their sutures and endo products from a defendant. Plaintiff further contends that the amount of the “discount” was such as to bring the price of defendants’ sutures and endo products below cost and, thus, constituted predatory pricing which enhanced defendants’ market power, raised barriers to entry and impeded the ability of plaintiff to compete.
Plaintiff contends that in order to avoid paying extra for the med-surg products hospitals needed as part of the med-surg basket, acute care providers declined to purchase sutures and endo products from plaintiff and instead purchased them from defendants. Plaintiff alleges that its business has been injured and that consumers have been injured in the following manner: less consumer choice among competing suture and endo product distributors; increased costs and reduced service; reduced access and barriers to entry to the sutures and endo products distribution market; chilled innovation within the medsurg supplies distribution market; and loss of competition among distributors to the acute care market.
Seven counts are listed in the complaint: a violation of § 1 of the Sherman Act alleging illegal tying (Count 1); a violation of § 2 of the Sherman Act alleging unlawful monopolization or attempted monopolization of the markets for the domestic distribution of sutures and endo products to acute care providers (Count 2); a violation of § 1 of the Sherman Act alleging conspiracy to restrain trade (Count 3); a violation of § 2 of the Sherman Act alleging conspiracy to monopolize (Count 4); a violation of § 3 of the Clayton Act alleging exclusive dealing (Count 5); a violation of K.S.A. 50-101 et. seq. alleging anti-competitive tying and bundling (Count 6); and’ unjust enrichment (Count 7).
II. STANDARDS GOVERNING DEFENDANTS’ MOTIONS TO DISMISS
FED.R.CIV.P. 8(a) requires that a complaint contain a “short and plain statement of the claim showing that the pleader is entitled to relief.” The Supreme Court has stated that a complaint must provide a defendant with “fair notice” of the claims against it and the grounds for relief. See Bell Atlantic Corp. v. Twombly,
III. COUNT ONE AND GLOBAL DEFENSES.
In this section of the court’s order, the court shall address defendants’ arguments against Count One and some of the arguments defendants have asserted broadly against all of the counts in the first amended complaint. The court shall address defendants’ statute of limitations arguments in a separate section of this opinion.
Count One alleges that each defendant individually engaged in illegal tying contracts in violation of § 1 of the Sherman Act. Section 1 of the Sherman Act prohibits “[e]very contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States.” 15 U.S.C. § 1. Any “restraint of trade” is not prohibited by § 1 of the Sherman Act, only “unreasonable restraints of trade.” Law v. NCAA,
“Generally, a tying arrangement, is illegal under § 1 of the Sherman Act if it can be shown that: (1) two separate products or services are involved; (2) the sale or agreement to sell one product or service is conditioned on the purchase of another; (3) the seller has sufficient economic power in the tying product market to enable it to restrain trade in the tied product market; and (4) a not insubstantial amount of interstate commerce in the tied product is affected.” Sports Racing Services, Inc. v. Sports Car Club of America, Inc.,
Whether an alleged restraint of trade is unreasonable depends upon a “rule of reason” or a “per se” analysis. A “rule of reason” analysis, the most commonly used method, requires weighing all of the circumstances of a case to decide whether a restrictive practice imposes an unreasonable restraint on competition. Gregory v. Fort Bridger Rendezvous Ass’n,
A. Per se analysis.
Count One does not state a plausible Sherman Act violation under per se analysis. The Tenth Circuit has stated that: “A tie-in constitutes a per se section 1 violation if the seller has appreciable economic power in the tying product market and if the arrangement affects a substantial volume of commerce in the tied product market.” Multistate Legal Studies, Inc. v. Harcourt Brace Jovanovich Legal and Professional Publications, Inc.,
The first amended complaint fails to state a per se tying claim for the following reasons. First, as discussed later in this decision, the court finds that any horizontal conspiracy allegations are insufficiently pled. Second, contracts between an individual defendant and a purchaser of med-surg supplies are vertical arrangements, and therefore less likely to be a per se violation. Third, the alleged market power of each individual defendant is insufficient for the defendant to be held liable in a per se tying case. See Jefferson Parish Hosp. Dist. No. 2 v. Hyde,
B. Rule of reason analysis
To properly allege a tying claim which satisfies the rule of reason analysis, a plaintiff must allege facts showing that the contract or agreement in question had a substantially adverse effect on competition in general. See Gregory,
C. Other arguments
1. Strict tie-ins versus discounts
Defendants argue that plaintiff cannot proceed upon a tying claim because defendants allow for separate purchases of med-surg supplies and sutures and endo products. As described previously, instead of requiring that med-surg supplies and suture and endo products be purchased together, each defendant is offering discounts on the sale of med-surg supplies if 90% of the purchaser’s sutures and endo products needs are purchased from the defendant. The court disagrees with defendants’ argument. The Tenth Circuit
2. Insufficient market power
Defendants contend that plaintiff has not asserted that defendants have sufficient market power in the tying product market to plausibly allege the ability to coerce a purchaser to buy sutures and endo products from defendants. As already noted, the first amended complaint states that the alleged tying activity has caused plaintiff to lose a significant number of customers. From this allegation (which must be considered as true) as well as plaintiffs allegations regarding predatory pricing, entry barriers, and parallel pricing behavior by two substantial competitors in the med-surg market, it is plausible to infer that each defendant has sufficient market power in the tying products to coerce buyers to accept the alleged tying arrangement.
3. Relevant market definition
A proper definition of “relevant market” is critical to determining whether a restraint of trade is unreasonable or
Defendants contend that Count One and the rest of plaintiff's antitrust claims must be dismissed because plaintiff has improperly confined its definition of the relevant market to domestic acute care providers who purchase med-surg supplies.
This is not an instance in which the court can determine that plaintiffs relevant market is flawed on its face. As suggested above, many courts recognize that the definition of the relevant market and a defendant’s power in that market are issues of fact. E.g., Todd v. Exxon Corp.,
After due consideration, the court cannot state at this time that plaintiffs conception of the relevant market or sub-market is so flawed that it renders plaintiffs claims implausible or impossible to consider.
4. Antitrust injury
Defendant Cardinal contends that all of plaintiffs antitrust claims must be dismissed because plaintiff has failed to properly allege the type of injury that antitrust laws are designed to remedy. We reject this contention. Plaintiff alleges that defendants’ tying arrangements reduce the level of competition in the distribution of sutures and endo products; that they limit a customer’s choice of sutures and endo products; and that they deprive customers of advantages in delivery costs and procedures. This is sufficient to allege an antitrust injury. See Palmyra Park Hosp., Inc. v. Phoebe Putney Mem’l Hosp.,
IV. COUNTS THREE AND FOUR
Counts Three and Four allege a conspiracy to violate §§ 1 and 2 of the Sherman Act. As mentioned earlier, § 1 prohibits among other agreements, conspiracies in restraint of trade or commerce. Section 2 of the Sherman Act prohibits persons from monopolizing, attempting to monopolize or conspiring to monopolize any part of interstate trade or commerce. 15 U.S.C. § 2. An agreement or conspiracy under federal antitrust laws is said to exist when “there is a unity of purpose, a common design and understanding, a meeting of the minds, or a conscious commitment to a common scheme.” West Penn Allegheny Health Sys. v. UPMC,
Plaintiff alleges that defendants did the same thing in response to plaintiffs success in selling suture and endo products; namely, defendants tied the sale of suture and endo products to the sale of other products in the med-surg basket. The first amended complaint (Doc. No. 19) contains the following allegations:
Defendants provide in their contracts that, if an acute care organization wants to purchase distributors’ products in the Med-Surg basket excluding sutures and endo, the customer must also purchase sutures and endo products from this distributor; otherwise, Defendants charge the hospital or other acute care organization a penalty in the form of a prohibitive distribution fee applicable to the entire Med-Surg basket. Defendants divide purchase requirements between Med-Surg products excluding sutures and endo, and sutures and endo products. If the acute care provider does not purchase 90% or more of its sutures and endo needs from Defendants, it must pay a penalty on its entire MedSurg spend. That penalty can range from 1 percent to 5 percent. ¶ 44. Defendants also employ the alternative tactic of repackaging distribution penalty programs as purported discount programs. Defendants offer a bundle of Med-Surg products, including sutures and endo products, for a so-called discounted distribution fee and eliminate the discount when sutures and endo are not included in the basket. ¶ 47.
[T]he allocation of this whole basket “discount” to sutures and endo products brings the price of the Defendants’ sutures and endo offerings below cost. ¶ 48.
This predatory pricing enhances Defendants’ market power, raises barriers to entry and impedes the ability of [plaintiff] to compete. ¶ 49.
These exclusionary practices clearly are directed at [plaintiff]. Sutures and endo are the only product categories in the entire Med-Surg basket subject to Defendants’ illegal tying and bundling arrangements. Further, [plaintiff] is the only significant specialty distributor of sutures and endo products. ¶ 50.
[T]he exclusionary practices directed at [plaintiff] and employed by [defendants] áre strikingly similar. ¶ 51.
The Defendants’ lock-step implementation of nearly identical penalty programs defies each distributor’s independent economic interests. One would expect, for example, in response to [defendant] Cardinal’s imposition of contractual penalties on acute care providers who seek to purchase from [plaintiff], that [defendant] 0 & M — acting independently— would seek these customers’ business by offering Med-Surg products without the penalty. Instead, [defendant] 0 & M imposes a similar regime of contractual penalties and bundling that does not challenge [defendant] Cardinal. In short, [defendants] present a united front against acute care providers’ dealing with [plaintiff]. ¶ 52.
There are no legitimate business justifications for Defendants’ anti-competitive practices. Any purported legitimate business justifications are mere pretexts. ¶ 53.
The Supreme Court has stated that when alleging a conspiracy in violation of antitrust laws, a complaint must contain “enough factual matter (taken as true) to suggest that an agreement was made.” Twombly,
[L]awful parallel conduct fails to bespeak unlawful agreement ... therefore, ... an allegation of parallel conduct anda bare assertion of conspiracy will not suffice. Without more, parallel conduct does not suggest conspiracy, and a eonclusory allegation of agreement at some unidentified point does not supply facts adequate to show illegality. Hence, when allegations of parallel conduct are set out in order to make a[n] [antitrust] claim, they must be placed in a context that raises a suggestion of a preceding agreement, not merely parallel conduct that could just as well be independent action.
Id. at 556-57,
In the case at bar, plaintiff is alleging that the parallel conduct described in the first amended complaint should be construed as circumstantial evidence of a conspiracy because, instead of challenging defendant Cardinal by offering its medsurg products without a penalty for purchasing sutures and endo products from a different distributor, defendant 0 & M employed a program similar to defendant Cardinal directed against plaintiff’s competition in the market for sutures and endo products. Plaintiff, however, does not explain why it would be more lucrative for defendant 0 & M to challenge defendant Cardinal instead of taking the approach that 0 & M allegedly has taken. Other courts have observed that “in a highly concentrated market, any single firm’s price and output decisions will have a noticeable impact on the market and on its rivals such that when any firm in that market is deciding on a course of action, any rational decision must take into account the anticipated reaction of the other firms.” In re Insurance Brokerage Antitrust Litigation,
Plaintiff does not allege any circumstances, aside from the alleged action against interest, which supposedly supply a factual context to support an inference that defendants had a prior agreement to engage in parallel conduct. Plaintiffs contention that defendants acted against interest is not sufficient to raise a plausible inference of conspiracy because there is no compelling logic supporting that contention. The fact that a defendant could have chosen a different strategy does not produce an inference that the choice of a strategy similar to that of a fellow competitor is a sign of conspiracy. In the absence of any other contextual support from which to infer a conspiracy, the court agrees with defendants that plaintiff has failed to adequately allege a conspiracy to violate the antitrust laws.
V. COUNTS TWO AND FOUR
Counts Two and Four of the first amended complaint allege violations of § 2 of the Sherman Act. Plaintiff alleges unlawful monopolization and attempted monopolization in Count Two; plaintiff alleges a conspiracy to monopolize in Count Four. To state a monopolization claim, a plaintiff must allege facts supporting an inference of: “1) the possession of monopoly power in the relevant market and 2) the willful acquisition or maintenance of that power as distinguished from growth or
To allege a conspiracy to monopolize claim, a plaintiff must plead facts which allege: “1) the existence of a combination or conspiracy to monopolize; 2) overt acts done in furtherance of the combination or conspiracy; 3) an effect upon an appreciable amount of interstate commerce; and 4) a specific intent to monopolize.” Lantec Inc. v. Novell, Inc.,
Defendants allege that plaintiffs monopolization and attempted monopolization claims are inadequately pleaded, in part, because plaintiffs have not alleged that defendants possess monopoly power or that defendants’ actions have produced a dangerous probability of attaining monopoly power. As noted before, plaintiff alleges that defendant O & M has 39% of the acute care market for the distribution of med-surg supplies and for sutures and endo products and that defendant Cardinal has 33% of those markets. This means, of course, that other companies share 28% of those markets.
The court agrees with defendants that plaintiff has failed to plead facts which demonstrate a real possibility that discovery would produce proof that defendants possess monopoly power or that defendants’ actions have produced a dangerous probability of attaining monopoly power. The Tenth Circuit held in Colorado Interstate Gas Co. v. Natural Gas Pipeline Co.,
In this case, plaintiffs allegations do not support a viable inference of monopolization. There are no allegations of market share or ability to control price and competition which support a reasonable inference that either defendant has monopoly power. The first amended complaint asserts that the alleged tying and discount programs raise barriers to entry and impede plaintiffs ability to compete, and that the alleged below-cost pricing has caused plaintiff to lose “a significant number of existing and potential customers.” ¶ 7. Plaintiff has also asserted in opposition to the motions to dismiss that high capital costs are an entry barrier. But, no facts are alleged to support an inference that defendants’ programs and practices, which allegedly began in 2008, have produced a dangerous probability of either defendant attaining monopoly power. Moreover, the substantial market share that each defendant possesses is a factor which undermines a claim that either defendant possesses monopoly power or a dangerous potential to attain such power. Bayer Schering Pharma AG v. Sandoz, Inc.,
As discussed earlier, plaintiffs allegations of conspiracy are insufficiently pled. The court does not believe the first amended complaint sets forth facts from which one can infer a reasonable possibility that defendants conspired to monopolize or conspired to attempt to monopolize the relevant markets in this case. Accordingly, the court rejects plaintiffs suggestion that the court should consider the aggregate market power of defendants in deciding whether plaintiff has adequately pleaded claims under § 2 of the Sherman Act. Moreover, it appears that most courts have rejected shared or joint monopoly arguments when analyzing § 2 claims, finding that such claims contradict the basic concept that a monopoly is the domination of a market by a single firm. E.g., Terminalift LLC v. International Longshore and Warehouse Union Local 29,
For these reasons, Counts Two and Four fail to state a claim.
VI. COUNT FIVE
Count Five of the first amended complaint alleges exclusive dealing in violation of § 3 of the Clayton Act against each defendant individually. This section makes it unlawful: “for any person engaged in commerce, in the course of such commerce, to ... make a sale or contract for sale of goods ... for use, consumption, or resale within the United States ... on the condition, agreement, or understanding that the lessee or purchaser thereof shall not use or deal in the goods ... of a competitor or competitors of the ... seller, where the effect of such lease, sale, or contract for sale or such condition, agreement, or understanding may be to substantially lessen competition or tend to create a monopoly in any line of commerce.” 15 U.S.C. § 14.
“To prove a violation under § 3 of the [Clayton] Act, a plaintiff must show the following: 1) that the violator is engaged in interstate commerce and that the alleged unlawful act occurred in the course of such interstate commerce, 2) the violation involved a contract for sale, a sale, or a lease, 3) that the agreement is for goods,
Plaintiff asserts that defendants have made sales of med-surg products based on the condition that the purchaser will not deal in plaintiffs sutures and endo products. Plaintiff further asserts that this “exclusive dealing” has foreclosed plaintiff from substantial portions of the markets for the distribution of sutures and endo products and has substantially lessened competition in those markets.
Defendants argue that defendants’ discount programs do not constitute exclusive dealing agreements for the purposes of the Clayton Act because the agreements permit purchasers to buy some percentage of sutures and endo products from distributors other than defendants. The Clayton Act, however, is not expressly limited to contracts which completely exclude the purchase of a competitor’s goods and courts have construed the Act as applying to contracts that are not 100% exclusive. ZF Meritor, LLC v. Eaton Corp.,
Defendants also argue that plaintiff has not alleged that the discount programs described in the first amended complaint are actually used by purchasers of sutures and endo products. Although no names are alleged by plaintiff, the court believes one can reasonably infer from the complaint that the discount programs are used and are the reason why plaintiff has lost customers it otherwise would have had. See Kay v. Bemis,
Similarly, the court finds that defendants’ arguments regarding the level of market foreclosure do not warrant the dismissal of plaintiffs exclusive dealing claim. A number of issues may be relevant to a consideration of whether an exclusive dealing arrangement forecloses a substantial part of the market. For instance, in Tampa Electric Co. v. Nashville Coal Co.,
Here, plaintiff alleges that defendants are foreclosing from plaintiffs competition a percentage of the market equivalent to each defendant’s market share for medsurg supplies, which is 39% for defendant O & M and 33% for defendant Cardinal. This is not an implausible claim and given the number of other factors which may be relevant to a rule of reason analysis, the court shall not decide at the pleading stage that plaintiff has failed to plead adequate foreclosure levels to go forward with Count Five.
VIL COUNTS SIX AND SEVEN-STATE LAW CLAIMS
A. Kansas Restraint of Trade Act— Count Six
Plaintiff asserts a violation of the Kansas Restraint of Trade Act (“KRTA”) in Count Six and makes only a general citation to K.S.A. “50-101 et seq.” Defendant Cardinal contends that this citation to K.S.A. 50-101 et seq. is inadequate to provide defendant with proper notice of the state law claims plaintiff is making because there are numerous sections to consider. While this argument has some allure, the general rule appears to be that a complaint need not point to- the appropriate statute or law in order to raise a claim for relief; a complaint may sufficiently raise a claim even if it points to no legal theory or even if it points to the wrong legal theory as a basis for that claim. Morris v. Schroder Capital Mgmt. Intern.,
Defendant O & M and defendant Cardinal further argue that Count Six should be dismissed because plaintiff only alleges lawful unilateral conduct. The court agrees that plaintiff has not adequately alleged illegal conspiratorial conduct. Plaintiff may still contend however that, in violation of K.S.A. 50-112, defendants made contracts or agreements “with a view or which tend to prevent full and free competition in the ... sale of articles imported into [Kansas].” While plaintiff has not adequately alleged a conspiracy to violate antitrust laws, plaintiff does allege contracts which plausibly fall within the language of K.S.A. 50-112 and constitute more than mere unilateral pricing policy. Therefore, we reject defendants’ contention that plaintiff has failed to state a claim under the KRTA.
B. Unjust Enrichment—Count Seven
Plaintiff asserts an unjust enrichment claim in Count Seven. The essence of plaintiff’s allegations is that plaintiff has had a “reduced presence” in the sutures and endo products markets and that defendants’ market share is greater in those markets because of defendants’ anti-competitive activities. This does not state a claim for unjust enrichment.
It appears undisputed that in Kansas the elements of an unjust enrichment claim are: 1) a benefit conferred; 2) an appreciation or knowledge of the benefit by the one receiving the benefit; and 3)
It is not plausible to consider plaintiffs reduced market presence as a benefit conferred upon defendants by plaintiff. “Confer” means to bestow, grant, give or contribute. Oxford English Dictionary, OED Online Version June 2013, available at www.oed.com. Plaintiff does not allege that it bestowed, granted or gave business to defendants. Plaintiff alleges that business customers or potential business customers were lured away from purchasing sutures and endo products from plaintiff and attracted to making such purchases from defendants by defendants’ tying, bundling or exclusive dealing contracts. While plaintiffs loss of business or “reduced market presence” may have benefited defendants, it was not a benefit conferred by plaintiff. See Wichita Clinic, P.A. v. Columbia/HCA Healthcare Corp.,
VIII. STATUTE OF LIMITATIONS AND LACHES
Defendant Cardinal argues that plaintiffs federal claims should be dismissed by virtue of the statute of limitations and the doctrine of laches. Both defendants argue that plaintiffs state law claims are barred by the statute of limitations. It is undisputed for the purposes of the motion to dismiss that plaintiffs federal damages claims are governed by a four-year statute of limitations (Champagne Metals v. Ken-Mac Metals, Inc.,
The statute of limitations and laches are affirmative defenses. Aldrich v. McCulloch Props., Inc.,
Defendant Cardinal contends that the facts from the complaint demonstrate that plaintiffs federal claims are probably barred, “[u]nless the challenged conduct occurred between December 5 and December 31, 2012.” Doc. No. 24, p. 25. But, defendant Cardinal does not establish that plaintiffs allegations show noncompliance with the statute of limitations or that plaintiff has unreasonably delayed bringing its claims. Therefore, the court shall reject defendant Cardinal’s arguments that plaintiffs federal claims are barred under the statute of limitations or laches.
Defendants’ argumentation suffers from the same flaw as regards the timeliness of plaintiffs state law claims. The complaint alleges that defendants initiated their alleged illegal bundling or tying activity in 2008. (Doc. No. 19, ¶ 43). Plaintiff filed this action on December 5, 2012. These allegations, accepted as true, do not demonstrate that defendants entered illegal tying, bundling or exclusive dealing contracts only prior to December 5, 2009, that is, more than three years prior to filing the original complaint in this case. See Tricorn, Inc. v. Electronic Data Systems Corp.,
IX. CONCLUSION
Consistent with the above-stated discussion, the court shall grant in part and deny in part defendants’ motions to dismiss, Doc. Nos. 23 and 27. The motions are granted as to Counts Two, Three, Four and Seven and denied as to Counts One, Five and Six. Doc. No. 23 is moot as to Cardinal Health Inc. The motion to dismiss filed as Doc. No. 25 is entirely moot. Plaintiff shall be granted leave to file a second amended complaint by August 30, 2013. The motion to amend the memorandum in support of the motion to dismiss filed by defendant Owen & Minor Distribution, Inc. (Doc. No. 45) is granted. The request for judicial notice (Doc. No. 29) shall be granted. The motion for oral argument (Doc. No. 48) is denied.
IT IS SO ORDERED.
Notes
. Two other defendants named in the first amended complaint, Cardinal Health, Inc. and Owens & Minor, Inc. have been voluntarily dismissed without prejudice. Doc. No. 42. This action makes moot a portion of the motion to dismiss filed as Doc. No. 23 and makes the motion to dismiss filed as Doc. No. 25 entirely moot.
. The court shall also rule as follows upon motions connected to the motions to dismiss. The unopposed motion to amend the memorandum in support of the motion to dismiss
. Defendant Cardinal has cited Bailey’s, Inc. v. Windsor Am., Inc.,
. Plaintiff also alleges that each product category within the broader market of med-surg products constitutes a relevant market or sub-market. Doc. No. 19, ¶¶ 25-26.
. The type of factual analysis described in Allen and Lockheed Martin occurred in Thurman Industries, Inc. v. Pay ’N Pak Stores, Inc.,
. This conclusion is supported by more recent reviews of case law. E.g., In re Pool Products Distribution Market Antitrust Litigation,
